Status:
RECRUITING
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Lead Sponsor:
Peking University First Hospital
Conditions:
Radiation Therapy
Targeted Therapy
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This is a prospective, single-center clinical trial designed to evaluate the safety and efficacy of combining stereotactic ablative body radiotherapy (SABR) with the targeted therapy Axitinib and the ...
Eligibility Criteria
Inclusion
- Histopathologically confirmed renal cell carcinoma with recurrent metastatic lesions confirmed by PET/CT or other systemic imaging.
- Patients with ≤5 metastatic lesions amenable to complete lesion coverage radiotherapy; or \>5 lesions with at least 3 suitable for radiotherapy as evaluated by the radiotherapy and imaging departments.
- Age between 18-80 years.
- Expected survival of ≥12 weeks.
- Measurable disease based on RECIST Version 1.1.
- ECOG performance status of 0-2.
Exclusion
- History of anti-PD-1 or PD-L1 antibody therapy, or radiotherapy.
- Use of corticosteroids or other immunosuppressants within 14 days before treatment.
- Autoimmune diseases.
- History of other malignancies.
- History of surgery within 28 days before treatment.
- Allergy to study drug components.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 20 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06889649
Start Date
January 1 2019
End Date
February 20 2028
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034